<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260947</url>
  </required_header>
  <id_info>
    <org_study_id>B5261005</org_study_id>
    <secondary_id>2014-003553-34</secondary_id>
    <nct_id>NCT02260947</nct_id>
  </id_info>
  <brief_title>Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints</brief_title>
  <official_title>A Double Blind, Double Dummy, Randomized, Placebocontrolled, 5 Period Cross-over Study To Examine The Effect of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the activity of 2 different doses of PF-06273340 on a panel of evoked
      pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thermal pain detection threshold</measure>
    <time_frame>0.5 - 4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultra-violet light sensitized pain detection threshold</measure>
    <time_frame>0.5 - 4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain tolerance threshold</measure>
    <time_frame>0.5 - 4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrical pain tolerance threshold</measure>
    <time_frame>0.5 - 4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cold pressor tolerance threshold</measure>
    <time_frame>0.5 - 4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain detection threshold</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain area under the visual analogue scale pain curve</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post test visual analogue scale</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post-cold pressor pain detection threshold</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post cold pressor pain tolerance threshold</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post cold pressor area under the visual analogue scale curve</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post cold pressor post test visual analogue scale</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned pain modulation response pain detection threshold</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned pain modulation pain tolerance threshold</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned pain modulation area under the visual analogue scale curve</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Condition pain modulation post test VAS</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain detection threshold</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain area under the visual analogue scale curve</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain post test visual analogue scale</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold pressor pain detection threshold</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold pressor area under the visual analogue scale curve</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold pressor post test visual analogue scale</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06273340 half life</measure>
    <time_frame>0.5 - 10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>PF-06273340 50 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>PF-06273340 400 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin 300 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 600 mg</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years, inclusive. Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG or clinical laboratory tests.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

          -  Subjects who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  A positive urine drug screen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <state>CL</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

